Baxter Healthcare Sa

Baxalta Gmbh

Nanotherapeutics, Inc.

Avir Green Hills Biotechnology

Avir Green Hills Biotechnology Research Development Trade Ag

Andrej Egorov

Markus Wolschek

Thomas Muster

Julia Romanova

Sabine Nakowitsch

Michael Bergmann

Brigitte Krenn

Oleg Ivanovich Kiselev

Elisabeth Roethl

Boris Ferko

Christian Kittel

Elisabeth Röthl

Ekaterina Romanovskaya-Romanko

Oleg Kiselev

The present invention provides a novel influenza virus wherein both the NS and the PB1 gene segments are modified and wherein the PB1-F2 open reading frame is modified by introduction of at least one stop codon. Specifically, the influenza virus is lacking functional NS1 and PB1-F2 proteins. Additionally, a vaccine formulation comprising the modified influenza virus is provided and its use for prevention of influenza vaccination.

Influenza virus

The present invention relates to a novel replication deficient influenza virus comprising a modified NS1 segment coding for a NS1 protein lacking a functional RNA binding domain and functional effector domain and having a heterologous sequence inserted between the splice donor site and the splice acceptor site of the NS gene segment. The virus can be used as vector for expression of various proteins like chemokines, cytokines or antigenic structures and to produce vaccines. A fusion peptide comprising part of the N-terminus of an NS1 protein and a signal sequence fused to the C-terminus of said NS1 peptide is also provided.

Replication deficient influenza virus for the expression of heterologous sequences

The present invention provides a method for producing pH-stable enveloped viruses wherein said viruses are used for infection of host cells under low pH conditions and for incubation with cell culture cells under conditions of low pH, as well as influenza viruses obtainable by this method which exhibit a high growth rate in cell culture, increased pH and temperature stability and which have human receptor specificity.

Method for production of pH stable enveloped viruses

The present invention provides a method for generating negative-strand, segmented RNA viruses using linear expression constructs in the presence of helper virus.

Method for generation of RNA virus

The present invention provides a method for generating negative-stranded segmented RNA viruses using linear expression constructs in the presence of helper virus.

The present invention provides a high growth reassortant influenza A virus having at least two gene segments of seasonal or pandemic strain origin, a PB1 gene segment of A/Texas/1/77 strain origin and a PA gene segment of A/Puerto Rico/8/34 (H1N1) origin coding for a PA protein comprising at least one amino acid modification at any one of positions 10, 275, 682, according to SEQ ID No. 1. Further provided are vaccine formulations comprising the reassortant influenza A virus of the invention.

High growth reassortant influenza A virus

The use of macrolide polyene antibiotics or derivatives or analogues thereof as culture supplement for the propagation of virus is described. Further pharmaceutical compositions comprising a virus and a macrolide polyene antibiotic or a derivative or analogue thereof and methods for using of macrolide polyene antibiotics for transfection and infection of cells as well as the use of macrolide polyene antibiotics for the isolation of virus from clinical samples are disclosed.

Growing community of inventors

Vienna, Austria

Andrej Egorov